Infinity Extends R&D Collaboration With Mundipharma, Gets Another $50 Million For PI3K Program

Mundipharma has once again reinforced its partnership with Infinity by committing an additional $50 million to the partnership, with the money to be used in 2013 to support the biotech’s ongoing development of Hedgehog pathway inhibitor IPI-926.